



ASX Announcement

FOR IMMEDIATE RELEASE

NEW CLINICAL TRIALS

SYDNEY, Australia, 13th April 2006: Australian medical technology company, Sirtex Medical Limited (ASX: SRX) announced today the start of two new clinical trials to be conducted in the USA. Both trials involve the use of SIR-Spheres[®], which is Sirtex Medical's lead product for the treatment of liver cancer. Both trials are designed to provide the evidence on which to launch much larger randomised clinical trials.

Trial 1: Capecitabine plus SIR-Spheres

The first trial will be conducted at the Fox Chase Cancer Centre (FCCC) and is designed to determine the safety, toxicity, and recommended dose of capecitabine (Xeloda) when administered concurrently with SIR-Spheres in patients with advanced metastatic liver cancer. The trial will also obtain preliminary evidence of clinical efficacy of the combination when administered to a cohort of patients with metastatic liver cancer that has spread from the colorectum (large bowel). FCCC is the fourth largest cancer hospital in USA and is renowned for the quality of its research and patient care.

Capecitabine is an anticancer drug that is becoming increasingly used to treat patients with a variety of cancer types, including metastatic colorectal cancer. Colorectal cancer that has spread to the liver is the commonest cancer type treated with SIR-Spheres. The reason for conducting this trial is that Sirtex has previously recommended that capecitabine not be used in conjunction with SIR-Spheres until there is adequate safety data for the combination treatment. This trial will provide that evidence and will also allow the design of a subsequent larger trial that more completely assess efficacy of the combination treatment.

Trial 2: SIR-Spheres in the treatment of Primary Liver Cancer

The second trial will evaluate the use of SIR-Spheres in the treatment of advanced primary liver cancer. Primary liver cancer is one of the commonest of all cancers in humans and particularly so in Asia. It is notoriously difficult to effectively treat and most patients succumb to the disease.

This trial will be undertaken conjointly at the University of Texas MD Anderson Cancer Centre and the Liver Cancer Centre of the University of Pittsburgh. Both institutions are world renowned for the quality of their research. The MD Anderson is the world's largest cancer hospital and the Liver Cancer Centre of the University of Pittsburgh one of the largest centres specialising in the treatment of liver cancer.

As reported to shareholders at the last Annual General Meeting, Sirtex Medical Limited has a strategy to undertake many clinical trials involving SIR-Spheres over the next several years and will announce each of these trials as they are activated.

Sirtex Medical Ltd is an international company, located in Australia, the United States and Germany. Sirtex Medical Ltd aims to become the world leader in liver cancer treatment products. The Company believes the unmet demand for effective treatment of liver cancer provides an opportunity for Sirtex products.

For more information, visit our website at www.sirtex.com.

**ANGELA LEARD
COMPANY SECRETARY**

**CONTACT: GILMAN WONG
CHIEF EXECUTIVE OFFICER
PH: +61-2-9936-1400**

#####